Wall Street Zen upgraded shares of Onconetix (NASDAQ:ONCO - Free Report) to a hold rating in a report published on Saturday.
Onconetix Stock Down 3.8%
NASDAQ ONCO traded down $0.16 during trading on Friday, hitting $4.10. The company had a trading volume of 729,590 shares, compared to its average volume of 106,855. The company's fifty day moving average is $6.05 and its 200-day moving average is $24.43. Onconetix has a one year low of $3.84 and a one year high of $1,190.00.
Onconetix (NASDAQ:ONCO - Get Free Report) last issued its quarterly earnings data on Thursday, June 12th. The company reported $21.25 EPS for the quarter. The business had revenue of $0.10 million during the quarter. Onconetix had a negative net margin of 2,913.71% and a negative return on equity of 514.04%.
Institutional Investors Weigh In On Onconetix
An institutional investor recently bought a new position in Onconetix stock. Millennium Management LLC purchased a new position in Onconetix, Inc. (NASDAQ:ONCO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 39,477 shares of the company's stock, valued at approximately $25,000. Millennium Management LLC owned approximately 0.48% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors and hedge funds.
About Onconetix
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
See Also
Before you consider Onconetix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onconetix wasn't on the list.
While Onconetix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
